Fumiyasu Shiozawa

This inventor holds 8 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 6 EPO patents. Top assignee: Taisho Pharmaceutical Co., Ltd.. Active years: 2010-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fumiyasu Shiozawa. Retrieved from https://idiyas.com/inventor/fumiyasu-shiozawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 2)

% Patents Active = 12.5

CIPO Patents = 3

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 7.3

ph-index = 4

Forward Citations = 22(Granted Patents)

Location History:

Toshima-ku, JP (2011 - 2015)
Tokyo, JP (2010 - 2016)

Company Filing History:

8 out of 314

Taisho Pharmaceutical Co., Ltd.

patents

Years Active: 2010-2016

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9422240 - Partially saturated nitrogen-containing heterocyclic compound (2016-08-23),

2. 9161945 - 4-isopropyl-6-methoxyphenyl glucitol compound (2015-10-20),

3. 8466113 - 4-isopropylphenyl glucitol compounds as SGLT1 inhibitors (2013-06-18),

4. 8048898 - [object Object] (2011-11-01),

5. 8022225 - Triazole derivative (2011-09-20),

6. 8022091 - Triazole derivative (2011-09-20),

7. 7994204 - Binding inhibitor of sphingosine-1-phosphate (2011-08-09),

8. 7678810 - Thiazole derivative (2010-03-16),

Title: Fumiyasu Shiozawa: Innovator in Pharmaceutical Compounds

Introduction

Fumiyasu Shiozawa is a notable inventor based in Toshima-ku, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 8 patents. His work focuses on developing compounds that have therapeutic effects, particularly in the treatment of diabetes and related conditions.

Latest Patents

Among his latest patents, Shiozawa has developed a partially saturated nitrogen-containing heterocyclic compound. This compound exhibits a superior PHD2 inhibitory effect, represented by a specific general formula. Additionally, he has created a 4-isopropyl-6-methoxyphenyl glucitol compound. This compound is designed to inhibit SGLT1 activity, which helps suppress glucose absorption, thereby addressing issues related to abnormal glucose tolerance and postprandial hyperglycemia in diabetes.

Career Highlights

Shiozawa is currently employed at Taisho Pharmaceutical Co., Ltd., where he continues to innovate and contribute to the pharmaceutical industry. His work is characterized by a commitment to improving health outcomes through the development of effective medicinal compounds.

Collaborations

He collaborates with esteemed colleagues such as Tetsuya Yabuuchi and Tetsuo Takayama, further enhancing the impact of his research and inventions.

Conclusion

Fumiyasu Shiozawa's contributions to pharmaceutical innovations demonstrate his dedication to advancing medical science. His patents reflect a focus on addressing critical health issues, particularly in diabetes management.

Profile summary based on public USPTO records.